INR 75.88
(-5.01%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 455.58 Million INR | -45.66% |
2022 | 283.74 Million INR | 3.48% |
2021 | 274.19 Million INR | 39.72% |
2020 | 196.24 Million INR | 12.72% |
2019 | 174.09 Million INR | 9.4% |
2018 | 159.13 Million INR | -1.08% |
2017 | 160.87 Million INR | -2.37% |
2016 | 164.76 Million INR | 7.64% |
2015 | 153.07 Million INR | -39.16% |
2014 | 251.61 Million INR | -26.87% |
2013 | 344.06 Million INR | 21.29% |
2012 | 283.67 Million INR | 105.5% |
2011 | 138.04 Million INR | 125.82% |
2010 | 61.13 Million INR | 13.86% |
2009 | 53.68 Million INR | -15.64% |
2008 | 63.64 Million INR | 545.16% |
2007 | 9.86 Million INR | 165.27% |
2006 | 3.71 Million INR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 21.87 Million INR | 67.27% |
2023 Q2 | 91.21 Million INR | -11.28% |
2023 Q4 | 48.95 Million INR | -42.38% |
2023 FY | 154.19 Million INR | -45.66% |
2023 Q3 | 84.96 Million INR | -6.86% |
2023 Q1 | 102.81 Million INR | 29.1% |
2022 FY | 283.74 Million INR | 3.48% |
2022 Q1 | 61.03 Million INR | -10.56% |
2022 Q2 | 67.55 Million INR | 10.7% |
2022 Q3 | 75.52 Million INR | 11.79% |
2022 Q4 | 79.63 Million INR | 5.45% |
2021 Q4 | 68.23 Million INR | 5.72% |
2021 Q1 | 61.56 Million INR | -0.29% |
2021 FY | 274.19 Million INR | 39.72% |
2021 Q2 | 79.85 Million INR | 29.72% |
2021 Q3 | 64.54 Million INR | -19.18% |
2020 Q1 | 33.46 Million INR | -27.98% |
2020 FY | 196.24 Million INR | 12.72% |
2020 Q4 | 61.74 Million INR | 21.05% |
2020 Q3 | 51 Million INR | 1.94% |
2020 Q2 | 50.03 Million INR | 49.51% |
2019 Q1 | 43.91 Million INR | -47.91% |
2019 FY | 174.09 Million INR | 9.4% |
2019 Q4 | 46.46 Million INR | 1.59% |
2019 Q3 | 45.73 Million INR | 20.42% |
2019 Q2 | 37.98 Million INR | -13.5% |
2018 Q2 | 37.55 Million INR | 0.36% |
2018 FY | 159.13 Million INR | -1.08% |
2018 Q4 | 84.29 Million INR | 116.46% |
2018 Q3 | 38.94 Million INR | 3.7% |
2018 Q1 | 37.42 Million INR | 0.0% |
2017 FY | 160.87 Million INR | -2.37% |
2016 FY | 164.76 Million INR | 7.64% |
2015 FY | 153.07 Million INR | -39.16% |
2014 FY | 251.61 Million INR | -26.87% |
2013 FY | 344.06 Million INR | 21.29% |
2012 Q1 | 57.69 Million INR | 0.0% |
2012 Q2 | -20.85 Million INR | -136.14% |
2012 Q3 | 57.77 Million INR | 377.05% |
2012 Q4 | 134.39 Million INR | 132.63% |
2012 FY | 283.67 Million INR | 105.5% |
2011 FY | 138.04 Million INR | 125.82% |
2010 FY | 61.13 Million INR | 13.86% |
2009 FY | 53.68 Million INR | -15.64% |
2008 FY | 63.64 Million INR | 545.16% |
2007 FY | 9.86 Million INR | 165.27% |
2006 FY | 3.71 Million INR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Amrutanjan Health Care Limited | 2.09 Billion INR | 78.244% |
Biofil Chemicals and Pharmaceuticals Limited | 6.82 Million INR | -6580.132% |
Caplin Point Laboratories Limited | 2.17 Billion INR | 79.049% |
FDC Limited | 3.49 Billion INR | 86.982% |
Gufic Biosciences Limited | 1.18 Billion INR | 61.605% |
Hikal Limited | 4.46 Billion INR | 89.794% |
Ind-Swift Laboratories Limited | 2.12 Billion INR | 78.552% |
IOL Chemicals and Pharmaceuticals Limited | 2.2 Billion INR | 79.301% |
Kilitch Drugs (India) Limited | 412.42 Million INR | -10.464% |
Medico Remedies Limited | 59.67 Million INR | -663.444% |
Nectar Lifesciences Limited | 932.7 Million INR | 51.154% |
Par Drugs and Chemicals Limited | 58.28 Million INR | -681.61% |
RPG Life Sciences Limited | 1.63 Billion INR | 72.144% |
Sequent Scientific Limited | 2.9 Billion INR | 84.3% |
Shilpa Medicare Limited | 3.33 Billion INR | 86.336% |
Sigachi Industries Limited | 579.88 Million INR | 21.436% |
Themis Medicare Limited | 1.12 Billion INR | 59.532% |
Unichem Laboratories Limited | 6.72 Billion INR | 93.226% |
Venus Remedies Limited | 1.91 Billion INR | 76.226% |
Wanbury Limited | 978.96 Million INR | 53.463% |
ZIM Laboratories Limited | 1.01 Billion INR | 55.029% |
Lupin Limited | 125.09 Billion INR | 99.636% |
Innova Captab Limited | 931.03 Million INR | 51.067% |
Ind-Swift Limited | 946.56 Million INR | 51.87% |
Bajaj HealthCare Limited | 985.34 Million INR | 53.764% |
Aurobindo Pharma Limited | 55.65 Billion INR | 99.181% |
Solara Active Pharma Sciences Limited | 2.55 Billion INR | 82.163% |
AstraZeneca Pharma India Limited | 2.47 Billion INR | 81.581% |
Mangalam Drugs & Organics Limited | 162.22 Million INR | -180.83% |
Morepen Laboratories Limited | 1.98 Billion INR | 77.077% |
Laurus Labs Limited | 11.9 Billion INR | 96.175% |
Aarti Drugs Limited | 1.16 Billion INR | 60.977% |
Glenmark Life Sciences Limited | 11.64 Billion INR | 96.086% |
Alembic Limited | 872.45 Million INR | 47.781% |
Alembic Pharmaceuticals Limited | 15.86 Billion INR | 97.129% |
Glenmark Pharmaceuticals Limited | 46.95 Billion INR | 99.03% |
Vaishali Pharma Limited | 84.02 Million INR | -442.176% |
Aarti Pharmalabs Limited | 3.07 Billion INR | 85.181% |
Jagsonpal Pharmaceuticals Limited | 438.55 Million INR | -3.884% |
Jubilant Pharmova Limited | 14.45 Billion INR | 96.848% |
Eris Lifesciences Limited | 4.94 Billion INR | 90.783% |
Windlas Biotech Limited | 1 Billion INR | 54.736% |
Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 99.705% |
Lincoln Pharmaceuticals Limited | 1.07 Billion INR | 57.588% |
Orchid Pharma Limited | 800.77 Million INR | 43.107% |
Albert David Limited | 1.02 Billion INR | 55.602% |
Hester Biosciences Limited | 908.84 Million INR | 49.872% |
Sakar Healthcare Limited | 204.07 Million INR | -123.24% |
Suven Pharmaceuticals Limited | 1.4 Billion INR | 67.523% |
Procter & Gamble Health Limited | 2.99 Billion INR | 84.791% |
Divi's Laboratories Limited | 14.17 Billion INR | 96.785% |
Mankind Pharma Limited | 29.27 Billion INR | 98.444% |
Neuland Laboratories Limited | 2.92 Billion INR | 84.45% |
J. B. Chemicals & Pharmaceuticals Limited | 14.79 Billion INR | 96.92% |
Zydus Lifesciences Limited | 125.21 Billion INR | 99.636% |
Wockhardt Limited | 8.48 Billion INR | 94.628% |
Bal Pharma Limited | 555.62 Million INR | 18.005% |
Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 99.525% |
Bliss GVS Pharma Limited | 1.41 Billion INR | 67.899% |
Alkem Laboratories Limited | 32.83 Billion INR | 98.613% |
Valiant Laboratories Limited | 138.02 Million INR | -230.065% |
Ajanta Pharma Limited | 30.46 Billion INR | 98.504% |
Aarey Drugs & Pharmaceuticals Limited | 14.21 Million INR | -3105.411% |
Granules India Limited | 10.31 Billion INR | 95.582% |
Medicamen Biotech Limited | 335.16 Million INR | -35.928% |
Ipca Laboratories Limited | 18.98 Billion INR | 97.601% |
Brooks Laboratories Limited | 51.18 Million INR | -790.162% |
Syncom Formulations (India) Limited | 345.63 Million INR | -31.812% |
Piramal Enterprises Limited | 63.65 Billion INR | 99.284% |
Torrent Pharmaceuticals Limited | 21.42 Billion INR | 97.873% |
NATCO Pharma Limited | 10.05 Billion INR | 95.47% |
Suven Life Sciences Limited | 109.75 Million INR | -315.112% |
Krebs Biochemicals & Industries Limited | 46.15 Million INR | -887.055% |
Strides Pharma Science Limited | 9.16 Billion INR | 95.028% |
Indoco Remedies Limited | 12.06 Billion INR | 96.223% |
Alpa Laboratories Limited | 127.38 Million INR | -257.658% |
Lasa Supergenerics Limited | 291.17 Million INR | -56.465% |
Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 85.193% |